APA (7th ed.) Citation

Asano, H., Oda, K., Yoshihara, K., Ito, Y. M., Matsumura, N., Shimada, M., . . . Enomoto, T. (2022). Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). Journal of Gynecologic Oncology, 33(4), 1. https://doi.org/10.3802/jgo.2022.33.e55

Chicago Style (17th ed.) Citation

Asano, Hiroshi, Katsutoshi Oda, Kosuke Yoshihara, Yoichi M. Ito, Noriomi Matsumura, Muneaki Shimada, Hidemichi Watari, and Takayuki Enomoto. "Phase II Study of Niraparib in Recurrent or Persistent Rare Fraction of Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052)." Journal of Gynecologic Oncology 33, no. 4 (2022): 1. https://doi.org/10.3802/jgo.2022.33.e55.

MLA (9th ed.) Citation

Asano, Hiroshi, et al. "Phase II Study of Niraparib in Recurrent or Persistent Rare Fraction of Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052)." Journal of Gynecologic Oncology, vol. 33, no. 4, 2022, p. 1, https://doi.org/10.3802/jgo.2022.33.e55.